A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy. Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More
Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is approved in patients who have received one to three… Read More
Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing. The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with… Read More
Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research. The study published in the European Journal of Medicinal Chemistry reveals a new gold-based compound that’s 27 times… Read More
Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More
Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More
Researchers at the University of Oxford in the UK have been awarded up to £600,000 ($786,525) from Cancer Research UK to create the world’s first vaccine to prevent ovarian cancer. OvarianVax is a vaccine that will teach the immune system to recognise and attack the earliest… Read More
